Wednesday, June 15, 2022 8:10:43 AM
Literature Database
Use of CytoSorb in a patient with hemorrhagic shock and multiple organ failure due to complicated secondary cesarean section
Dr. Mirko Brenni und Dr. Julien Marrel | Department for Anesthesiology, Intensive Care and Emergency Medicine, See-Spital Horgen, Horgen, Switzerland
06/15/2022
New!Case of the week
Download documentDownload document
Summary
CoW 24/2024 – This case reports on a 31-year-old previously healthy female patient, who was admitted post-operatively to the intensive care unit (ICU) with hemorrhagic shock and dilutional/ disseminated intravascular coagulopathy following secondary cesarean section with uterine atony, after already two revisions and ultimately an emergency hysterectomy.
Case presentation
On admission to the ICU, the patient was ventilated (pressure-controlled ventilation, with an FiO2 of 0.8), hemodynamically unstable with high catecholamine requirements. For hemodynamic stabilization, the patient was given norepinephrine up to 70 µg/min and dobutamine up to 300 µg/min in addition to fluid resuscitation. Moreover, the intravascular oncotic pressure was increased by an albumin infusion. While in shock, lactate levels were 10 mmol/l accompanied by severe metabolic acidosis
Also, following perioperative mass transfusion (including 9 red cell concentrates, 12 litres of Ringer’s solution) in postpartum hemorrhagic shock, she had dilutional and disseminated intravascular In accordance with repeated rotational thromboelastometry (ROTEM) measurements and a confirmed decrease in hemoglobin and platelet levels, as well as an increased bleeding tendency with prolonged aPTT, increased INR and fibrinogen deficiency, she received coagulation factors (a total of 15 g fibrinogen, 4500 IU human prothrombin complex (PPSB), 6000 IU blood coagulation factor XIII, 2000 mg tranexamic acid, 6 g calcium) as well as two platelet concentrates. As a result, her coagulative state was largely normalized intraoperatively under ROTEM control, and there were no further indications of post-operative bleeding
Chest X-ray examination showed bilateral pleural effusions and evidence of pulmonary hyperhydration, most probably due to the initial massive volume replacement therapy with increased capillary leakage, however without signs of pulmonary infiltrates
There was also a marked increase in troponin and creatine kinase values. Given the hemorrhagic shock situation, it was assumed that there was ischemic myocardial damage in the context of a type 2 acute coronary syndrome
Several hours post-operatively, inflammatory markers were clearly elevated: leukocytes 18.4 G/l, C-Reactive Protein [CRP] 62.5 mg/l and Interleukin [IL-6] 119 ng/l
Due to a confirmed nitrite-positive urinary tract infection, antibiotic therapy with co-amoxicillin was started for a total of 7 days. Repeated urine cultures, however, were negative on all measurements, while no bacterial growth could be detected in subsequent microbiological examinations
On the first postoperative day, there was also a marked increase in aminotransferases (aspartate aminotransferase [AST] 779 U/l, alanine aminotransferase [ALT] 132 U/l) indicating a shock-induced ischemic hepatopathy
Moderate ascites with anasarka was also found in the context of the pronounced fluid resuscitation. During the post-operative course, 1000-3000 mls of wound drainage per day was recorded
Due to acute anuric renal failure with hyperkalemia and hyperphosphatemia, continuous renal replacement therapy (CRRT) was started early, i.e. about 2 hours after admission to the ICU
Given the pronounced hemodynamic instability with progressive multi-organ failure in the context of severe hyperinflammation following mass transfusion, a CytoSorb cytokine adsorber was started simultaneously with CRRT
Treatment
Treatment with CytoSorb was performed for a period of about 48 hours
CytoSorb was used in combination with CRRT (Prismaflex, Baxter) run in CVVHDF mode
Anticoagulation: regional citrate. After the onset of citrate accumulation in the context of the most severe shock state with severe lactic acidosis, continuous veno-venous hemodiafiltration (CVVHDF) could be continued without problems following adjustment of hemodiafiltration settings
Position of the CytoSorb adsorber: post-hemofilter
Measurements
Hemodynamics and norepinephrine requirements
Lactate
Inflammatory parameters (CRP, Procalcitonin [PCT], ferritin, IL-6)
Fluid balance (colloids and crystalloids)
Oxygenation/ventilation
Results
Catecholamine therapy with norepinephrine could already be reduced to 3-5 µg/min 24 hours after initiation of combined CRRT/CytoSorb therapy after generous fluid substitution including album administration
Lactate levels also normalized on the first postoperative day
One day post-operatively, leukocytes were 14.1 G/l, CRP 72.5 mg/l, PCT 1.7 ng/ml, ferritin 787.7 µg/l and IL-6 86.4 ng/l
Following hemodynamic stabilization, consistent negative balancing could be achieved from day 4 onwards
The clinical pulmonary hyperhydration improved daily under negative balancing while chest X-ray examination showed that the pleural effusions had regressed. There was no evidence of transfusion-associated acute lung injury (TRALI). Weaning was also unproblematic, extubation was performed after neurological improvement on day 7
Patient Follow-Up
Due to a recurrent febrile episode in the antibiotic window, another sampling was performed, confirming the growth of Pseudomonas aeruginosa and Enterococcus faecium in the abdominal wound discharge. Consequently, antibiotic therapy was initially changed to piperacillin/tazobactam and daptomycin (for acute renal failure), and was then, according to the resistogram, switched from piperacillin/tazobactam to meropenem and continued for a total of 14 days. Following another recurrence of fever and ultrasound-guided puncture of an intra-abdominal hematoma, Candida albicans was detected in the collected sample After initiating antifungal therapy with fluconazole, inflammatory parameters decreased over time
After a total of 7 days of CVVHDF with an increase in diuresis, a first discontinuation attempt was started a few days later, which resulted in a renewed increase in creatinine and urea plasma levels. Therefore, intermittent hemodialysis was started and continued until transfer of the patient to a rehabilitation unit
Following an initial delayed recovery phase (despite reduced sedation, vigilance was still reduced), extubation was finally achieved without complications after a total of 7 days of invasive ventilation. Gas exchange was unproblematic. Due to persistent dyspnoea, a lung scintigraphy was performed without evidence of pulmonary embolism
After extubation, the patient was temporarily disoriented with hallucinations, which was interpreted as multifactorial delirium. The symptoms improved rapidly and there were no cognitive impairments. In the course of the patient’s stay, she developed loss of vision in the right eye, which, after magnetic resonance and ophthalmological examination, was interpreted as ischemic optic neuropathy in the context of the severe shock event
During the entire intensive care stay, the patient required a total of 7 units of red blood cells. Substrates remained within the normal range and erythropoietin was administered weekly in the presence of dialysis-dependent renal insufficiency with hyporegenerative anemia. At discharge, severe anemia persisted with an Hb of 63 g/l, however with measurable reticulocytosis.
The patient was discharged to a rehabilitation facility after a total hospital stay of 31 days
Conclusions
In this patient with hemorrhagic shock and multiple organ failure due to complicated secondary cesarean section, the post-operative use of CytoSorb, in addition to correcting hypoalbuminemia, led to hemodynamic stabilization by controlling hyperinflammation
According to the authors, CytoSorb therapy in this complex case presumably contributed to gaining control over the hyperinflammation triggered by the initial mass transfusion within a few hours
Hemoadsorption with CytoSorb in combination with CRRT was safe and easy to perform in this challenging setting.
Recent CTSO News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 09:25:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/01/2024 09:22:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 12:06:10 PM
- CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update • GlobeNewswire Inc. • 10/01/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/01/2024 04:15:18 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/26/2024 09:05:05 PM
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/26/2024 09:14:03 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/26/2024 09:11:21 PM
- CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress • GlobeNewswire Inc. • 07/17/2024 11:00:00 AM
- CytoSorbents Secures $20 Million Credit Facility • GlobeNewswire Inc. • 07/02/2024 11:00:00 AM
- CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
FEATURED SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service To Enhance Natural Rubber Industry's Ability to Report on Sustainable and Ethical Supply Chains • Oct 3, 2024 7:00 AM
North Bay Resources Announces Assays up to 5 oz/ton Gold, 1.5 oz/ton Platinum, 0.5 oz/ton Palladium, and 0.5 oz/ton Rhodium at Mt. Vernon Gold Mine, Sierra County, California • NBRI • Oct 4, 2024 9:15 AM
Basanite, Inc. Appoints Ali Manav as Interim Chief Executive Officer • BASA • Oct 3, 2024 9:15 AM
Integrated Ventures Announces Launch of MedWell Facilities, LLC and Lease Agreement with Giant Fitness Clubs • INTV • Oct 3, 2024 8:45 AM
Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • NVS • Oct 3, 2024 8:45 AM
Transforming Alzheimer's Treatment: Innovative Combinations to Boost Cognition • PFE • Oct 2, 2024 9:00 AM